Somatostatin receptor subtype 2 (SSTR2) is present at a high incidence in neuroendocrine tumors (NETs) and therefore is an ideal target for imaging and therapy of this malignant disease. The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.